- Molecular NameDuloxetine
- Synonym(+-)-duloxetine; Duloxetine HCl; Duloxetine Hydrochloride
- Weight297.422
- Drugbank_IDDB00476
- ACS_NO116539-59-4
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)4.03
- pka9.34
- LogD (pH=7, predicted)1.55
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)-1.65
- LogSw (predicted, AB/LogsW2.0)0.08
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors1
- No.of HBond Acceptors2
- No.of Rotatable Bonds6
- TPSA49.5
- StatusFDA approved
- AdministrationN/A
- PharmacologyA serotonin-norepinephrine reuptake inhibitor
- Absorption_valueN/A
- Absorption (description)Orally administered duloxetine hydrochloride is well absorbed.
- Caco_2N/A
- Bioavailability50.0
- Protein binding95.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP2D6 and CYP1A2 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. The major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.
- Half life12.1 h
- Excretion70% in urine, 20% in feces
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include tremors, convulsions, reduced activity, slow pupillary response, intermittent tremors, and rigidity.
- LD50 (rat)LD50=491 mg/kg
- LD50 (mouse)N/A